GlassScriptPhysician profile
Ankita Gupta
NPI 1912315862
$2,571.73
in general payments reported to CMS, 2019-2025
19 companies · $61.21 in 2025
The $61.21 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $525 · 2020: $235 · 2021: $35.77 · 2022: $348 · 2023: $842 · 2024: $525 · 2025: $61.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $877 · Consulting Fee: $525 · Education: $26.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $877.34 |
| Consulting Fee | $525.00 |
| Education | $26.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $938.71 | 2019-2024 | Imfinzi |
| Merck Sharp & Dohme LLC | $510.95 | 2019-2023 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $212.70 | 2020-2023 | Enhertu, Injectafer |
| Tersera Therapeutics LLC | $125.81 | 2021-2023 | Zoladex |
| Alexion Pharmaceuticals, INC. | $121.87 | 2022 | |
| Emd Serono, INC. | $113.70 | 2023 | Bavencio |
| Seagen INC. | $103.17 | 2019-2023 | Adcetris |
| Amgen INC. | $102.53 | 2019-2023 | Lumakras |
| Astellas Pharma US INC | $99.99 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $39.52 | 2023 | Imbruvica |
| Takeda Pharmaceuticals U.S.A., INC. | $35.70 | 2019-2020 | |
| Abbvie INC. | $33.25 | 2025 | |
| Tempus Ai, INC | $27.96 | 2025 | Xt Cdx |
| Genentech USA, INC. | $23.09 | 2023 | Perjeta, Herceptin, Kadcyla |
| Glaxosmithkline, LLC. | $20.43 | 2023 | Zejula, Jemperli |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $17.71 | 2020 | |
| Beigene USA, INC. | $16.83 | 2023 | Brukinsa |
| Btg International INC. | $14.50 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ankita Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.